Molecular and Translational Oncology Research

分子和转化肿瘤学研究

• 批准号: 10202497
• 负责人: JOHN BLENIS
• 金额: $ 28.53万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10202497
• 关键词: Molecular; Oncology; Research

ABSTRACT The past decade, an explosion of research and technological achievements in molecular oncology and genomics have offered an unprecedented opportunity to transform patient care. This shift in the traditional cancer research paradigm, demands for more sophisticated skills to be acquired by cancer scientists. We are requesting support via a new T32 training grant for the research training of four postdoctoral fellows in Molecular and Translational Oncology Research (MTOR) at Weill Cornell Medicine (WCM). WCM will provide funding for an additional fifth training slot. The objective of this program is to recruit the best possible candidates with a solid foundation in basic science and train them in molecular and translational oncology so that they can apply their knowledge to address important clinically unmet needs in the prevention, diagnosis, and treatment of cancer patients. MTOR trainees will receive program support for two years during which they will follow a structured and rigorous postdoctoral training path. The MTOR program is a joint effort of 17 outstanding WCM preceptors and co-mentors, and a dense network of clinical collaborators, who are international leaders in their respective fields. Trainees will further profit from the leveraging of institutional resources such as the Sandra and Edward Meyer Cancer Center and Weill Cornell's Clinical and Translational Science Center (CTSC). MTOR's highly personalized training plan will include 1) individual development plans and customized workplans; 2) rigorous translationally focused research training; 3) hands-on experience in cutting-edge methodologies; and 4) a comprehensive curriculum of innovative core and ancillary skill acquisition workshops, including writing, leadership, communication, and entrepreneurial perspectives. We anticipate a pool of at least 300 candidates. We have assembled an outstanding roster of external and internal advisory committee members with the mandate to evaluate the program and provide specific recommendations to improve its efficiency. MTOR has a strong diversity focus and through its rigorous, structured and highly personalized curriculum, seeks to train the future leaders in translational cancer research in the USA.

摘要 在过去的十年中，分子肿瘤学和基因组学的研究和技术成就的爆炸式增长， 提供了一个前所未有的机会来改变病人护理。这种传统癌症研究范式的转变， 需要癌症科学家掌握更复杂的技能。我们正在请求通过新的T32支持 培训补助金，用于分子和转化肿瘤学研究的四名博士后研究员的研究培训 Weill Cornell Medicine（WCM）WCM将为额外的第五个培训时段提供资金。的 该计划的目标是招募最好的候选人在基础科学和培训的坚实基础 他们在分子和转化肿瘤学，使他们能够运用自己的知识，以解决重要的临床 在癌症患者的预防、诊断和治疗方面未满足的需求。MTOR学员将获得计划 两年的支持，在此期间，他们将遵循结构化和严格的博士后培训路径。 该计划是17位杰出的WCM导师和共同导师的共同努力，以及一个密集的临床网络。 合作者，他们是各自领域的国际领导者。学员将从杠杆作用中进一步获益 机构资源，如桑德拉和爱德华迈耶癌症中心和威尔康奈尔的临床和 翻译科学中心（CTSC）。MTOR高度个性化的培训计划将包括1）个人 发展计划和定制的工作计划; 2）严格的以实践为重点的研究培训; 3）实践 尖端方法的经验;以及4）创新核心和辅助技能的综合课程 收购研讨会，包括写作，领导力，沟通和创业的观点。我们预计 至少有300名候选人。我们已经组建了一个优秀的外部和内部咨询委员会名册 成员的任务是评估该方案，并提出具体建议，以提高其效率。 MTOR有一个强大的多元化重点，并通过其严格的，结构化的和高度个性化的课程，旨在 培养美国转化癌症研究的未来领导者。

项目成果

System-wide transcriptome damage and tissue identity loss in COVID-19 patients.

• DOI: 10.1016/j.xcrm.2022.100522
• 发表时间: 2022-02-15
• 期刊: Cell reports. Medicine
• 作者: Park J;Foox J;Hether T;Danko DC;Warren S;Kim Y;Reeves J;Butler DJ;Mozsary C;Rosiene J;Shaiber A;Afshin EE;MacKay M;Rendeiro AF;Bram Y;Chandar V;Geiger H;Craney A;Velu P;Melnick AM;Hajirasouliha I;Beheshti A;Taylor D;Saravia-Butler A;Singh U;Wurtele ES;Schisler J;Fennessey S;Corvelo A;Zody MC;Germer S;Salvatore S;Levy S;Wu S;Tatonetti NP;Shapira S;Salvatore M;Westblade LF;Cushing M;Rennert H;Kriegel AJ;Elemento O;Imielinski M;Rice CM;Borczuk AC;Meydan C;Schwartz RE;Mason CE
• 通讯作者: Mason CE

The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases.

• DOI: 10.1126/sciadv.abg1964
• 发表时间: 2021-11-05
• 期刊: Science advances
• 影响因子: 13.6
• 作者: Marullo R;Castro M;Yomtoubian S;Calvo-Vidal MN;Revuelta MV;Krumsiek J;Cho A;Morgado PC;Yang S;Medina V;Roth BM;Bonomi M;Keshari KR;Mittal V;Navigante A;Cerchietti L
• 通讯作者: Cerchietti L

Lineage Reversion Drives WNT Independence in Intestinal Cancer.

• DOI: 10.1158/2159-8290.cd-19-1536
• 发表时间: 2020-10
• 期刊: Cancer discovery
• 影响因子: 28.2
• 作者: Han T;Goswami S;Hu Y;Tang F;Zafra MP;Murphy C;Cao Z;Poirier JT;Khurana E;Elemento O;Hechtman JF;Ganesh K;Yaeger R;Dow LE
• 通讯作者: Dow LE

Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.

• DOI: 10.1038/s41467-021-23780-y
• 发表时间: 2021-06-07
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Brady NJ;Bagadion AM;Singh R;Conteduca V;Van Emmenis L;Arceci E;Pakula H;Carelli R;Khani F;Bakht M;Sigouros M;Bareja R;Sboner A;Elemento O;Tagawa S;Nanus DM;Loda M;Beltran H;Robinson B;Rickman DS
• 通讯作者: Rickman DS

The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.

通过基因组转录组和单细胞蛋白标记物分析转移性上尿路上皮癌的演变。

• DOI: 10.1038/s41467-024-46320-w
• 发表时间: 2024
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Ohara,Kentaro;Rendeiro,AndréFigueiredo;Bhinder,Bhavneet;Eng,KennethWha;Ravichandran,Hiranmayi;Nguyen,Duy;Pisapia,David;Vosoughi,Aram;Fernandez,Evan;Shohdy,KyrillusS;Manohar,Jyothi;Beg,Shaham;Wilkes,David;Robinson,BrianD;Kha
• 通讯作者: Kha